Results 301 to 310 of about 174,356 (352)
GLİOBLASTOMLARDA BRAF V600E MUTASYON VE BRAF VE1 İMMUNEKSPRESYON PROFİLİ
, 2017 TOSUNER, ZEYNEP +4 more
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
BRAF Heterogeneity in Melanoma
Current Treatment Options in Oncology, 2021In the era of molecular targeted therapy, the accurate detection of BRAF mutation in melanoma has become increasingly important. With the advances of molecular analyses and immunohistochemistry, the presence of BRAF mutational heterogeneity in melanoma has been widely recognized.
Takamichi Ito +5 more
openaire +2 more sources
Combined BRAF and MEK inhibition in BRAF-mutant NSCLC
The Lancet Oncology, 2016Refers to Planchard D, Besse B, Groen HJM, Souquet P, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial ...
Gareth, Rivalland, Paul, Mitchell
openaire +2 more sources